HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

Abstract
Mutations in codon 132 of isocitrate dehydrogenase (IDH) 1 are frequent in diffuse glioma, acute myeloid leukemia, chondrosarcoma and intrahepatic cholangiocarcinoma. These mutations result in a neomorphic enzyme specificity which leads to a dramatic increase of intracellular D-2-hydroxyglutarate (2-HG) in tumor cells. Therefore, mutant IDH1 protein is a highly attractive target for inhibitory drugs. Here, we describe the development and properties of BAY 1436032, a pan-inhibitor of IDH1 protein with different codon 132 mutations. BAY 1436032 strongly reduces 2-HG levels in cells carrying IDH1-R132H, -R132C, -R132G, -R132S and -R132L mutations. Cells not carrying IDH mutations were unaffected. BAY 1436032 did not exhibit toxicity in vitro or in vivo. The pharmacokinetic properties of BAY 1436032 allow for oral administration. In two independent experiments, BAY 1436032 has been shown to significantly prolong survival of mice intracerebrally transplanted with human astrocytoma carrying the IDH1R132H mutation. In conclusion, we developed a pan-inhibitor targeting tumors with different IDH1R132 mutations.
AuthorsStefan Pusch, Sonja Krausert, Viktoria Fischer, Jörg Balss, Martina Ott, Daniel Schrimpf, David Capper, Felix Sahm, Jessica Eisel, Ann-Christin Beck, Manfred Jugold, Viktoria Eichwald, Stefan Kaulfuss, Olaf Panknin, Hartmut Rehwinkel, Katja Zimmermann, Roman C Hillig, Judith Guenther, Luisella Toschi, Roland Neuhaus, Andrea Haegebart, Holger Hess-Stumpp, Markus Bauser, Wolfgang Wick, Andreas Unterberg, Christel Herold-Mende, Michael Platten, Andreas von Deimling
JournalActa neuropathologica (Acta Neuropathol) Vol. 133 Issue 4 Pg. 629-644 (04 2017) ISSN: 1432-0533 [Electronic] Germany
PMID28124097 (Publication Type: Journal Article)
Chemical References
  • Aniline Compounds
  • Antineoplastic Agents
  • BAY 1436032
  • Benzimidazoles
  • Enzyme Inhibitors
  • Glutarates
  • Recombinant Proteins
  • alpha-hydroxyglutarate
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
Topics
  • Aniline Compounds (chemistry, pharmacokinetics, pharmacology, toxicity)
  • Animals
  • Antineoplastic Agents (chemistry, pharmacokinetics, pharmacology, toxicity)
  • Astrocytoma (drug therapy, enzymology, genetics)
  • Benzimidazoles (chemistry, pharmacokinetics, pharmacology, toxicity)
  • Brain Neoplasms (drug therapy, enzymology, genetics)
  • Cell Line, Tumor
  • Cell Survival (drug effects, physiology)
  • Colonic Neoplasms (drug therapy, enzymology, genetics)
  • Enzyme Inhibitors (chemistry, pharmacokinetics, pharmacology, toxicity)
  • Escherichia coli
  • Female
  • Glutarates (metabolism)
  • HEK293 Cells
  • Humans
  • Isocitrate Dehydrogenase (antagonists & inhibitors, genetics, metabolism)
  • Mice, Inbred BALB C
  • Mice, Nude
  • Mutation
  • Recombinant Proteins (genetics, metabolism)
  • Sarcoma (drug therapy, enzymology, genetics)
  • Sf9 Cells
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: